» Articles » PMID: 2847746

A Mu-opioid Receptor-filter Assay. Rapid Estimation of Binding Affinity of Ligands and Reversibility of Long-lasting Ligand-receptor Complexes

Overview
Date 1988 Oct 15
PMID 2847746
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A filter-associated binding technique, originally described by Leysen and Gommeren [J. Receptor Res. 4, 817 (1984); Drug Dev. Res. 8, 119 (1986)], was focused on the study of mu-opioid receptor sites. The interesting binding features of 3H-Sufentanil, a mu-selective radioligand, permitted such a filter procedure to be performed. Its application was 3-fold. A 5-min binding assay allowed us to verify that specific 3H-Sufentanil binding to filter-absorbed rat brain membranes was endowed with the known kinetic and equilibrium binding properties of membrane-bound mu-opioid receptor sites. Moreover, the filtration technique allowed us to get rapid information about the dissociation rates of unlabelled compounds from the receptor sites. In practice, membranes, preincubated with high concentrations of cold drugs, were absorbed to filters. Dissociation was achieved by repeatedly applying buffer samples on the filter, and monitored by the recovery in free specific 3H-Sufentanil binding sites. Finally, such a dissociation procedure, improved by a washing buffer at high ionic strength, was found to be much more efficient and attractive than the classical dilution-centrifugation procedure, especially for slowly-dissociating compounds. Special attention was paid to the discrimination between pseudo-irreversible binding of drugs and stable covalent labelling of mu-opioid receptor sites (either by affinity or photoaffinity probes), particularly when unlabelled ligands were the only tools available.

Citing Articles

Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.

Moss R, Pryor M, Baillie R, Kudrycki K, Friedrich C, Reed M PLoS One. 2020; 15(6):e0234683.

PMID: 32544184 PMC: 7297366. DOI: 10.1371/journal.pone.0234683.


Binding kinetics of ligands acting at GPCRs.

Sykes D, Stoddart L, Kilpatrick L, Hill S Mol Cell Endocrinol. 2019; 485:9-19.

PMID: 30738950 PMC: 6406023. DOI: 10.1016/j.mce.2019.01.018.


Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A EMBO J. 1998; 17(4):886-97.

PMID: 9463367 PMC: 1170438. DOI: 10.1093/emboj/17.4.886.


The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.

Kieffer B, Befort K, Gaveriaux-Ruff C, Hirth C Proc Natl Acad Sci U S A. 1992; 89(24):12048-52.

PMID: 1334555 PMC: 50695. DOI: 10.1073/pnas.89.24.12048.